Metrics as of 10/16/2026, 08:17 AM (Berlin time), refresh in progress.
Kymera Therapeutics Stock
Kymera Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Nello Mainolfi
- Employees
- 273
- Market cap
- $8.9 B
- IPO
- 21/08/2020
Kymera Therapeutics, Inc. is a healthcare company based in Watertown, US, dedicated to the discovery and development of pioneering small molecule therapeutics. The company's business model focuses on harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. Its…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Kymera Therapeutics stock: price history
1D
+1.2%
1W
-1.1%
1M
-4.4%
6M
+25.5%
YTD
+39.0%
1Y
+72.0%
2Y
+141.4%
5Y
+89.1%
10Y
–
Next earnings date
Next earnings date
03/11/2026 (in 17 days)
Volatility around earnings
~22% stronger price swings than usual
Ask the agents about Kymera Therapeutics
Analyst assessment of Kymera Therapeutics
PRICE TARGET LOW
US$97.00
CONSENSUS
US$138.20
MEDIAN
US$139.00
PRICE TARGET HIGH
US$180.00
0
STRONG BUY
24
BUY
3
HOLD
0
SELL
0
STRONG SELL
27
TOTAL · Buy
As of: 05/10/2026
Kymera Therapeutics stock metrics
P/E
-33.27
P/B
7.03
EV/EBITDA
-30.38
RETURN ON EQUITY
-4.1%
NET MARGIN
-94.2%
DEBT/EQUITY
0.05
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
80.3%
FLOAT SHARES
66,039,884
AVG. DAILY VOLUME (30D)
820,749
Insider transactions (SEC)
Mainolfi Nello
Mainolfi Nello
Mainolfi Nello
Mainolfi Nello
Mainolfi Nello
Institutional holders
Comparable stocks
Frequently asked questions about Kymera Therapeutics stock
What does Kymera Therapeutics do?
Kymera Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Nello Mainolfi, the company employs around 273 people.
The IPO was on 21/08/2020; the stock trades on NASDAQ under the ticker KYMR.
What do analysts say about Kymera Therapeutics stock?
27 analysts rate the stock, the consensus is Buy (as of 05/10/2026).
The average price target is US$138.20, ranging from US$97.00 to US$180.00, with a median of US$139.00.
This is an external assessment, not a statement by Market Jury.
When does Kymera Therapeutics report next?
The next earnings date is 03/11/2026.
Around past earnings, price swings were roughly 22% stronger than usual.
Does Kymera Therapeutics pay a dividend?
No, Kymera Therapeutics currently does not pay a dividend.
Which stocks are comparable to Kymera Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Kymera Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Kymera Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.